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Abstract
Background Non-arteritic anterior ischemic optic neuropa-
thy (NAION) is a multifactorial disease that is caused by an
infarction of the vessels that supply the optic nerve head.
This study aims at evaluating the role of traditional and
emerging cardiovascular risk factors on the development of
NAION.
Methods A total of 85 newly diagnosed NAION patients
and 107 age- and gender-matched healthy controls were
studied. All participants underwent blood testing for
homocysteine and lipoprotein(a). Plasma levels of vitamin
B6 and B12, and folic acid were also determined. Plasma
values of all these parameters were evaluated as continuous
variables, by a logarithmic transformation. In addition,
traditional cardiovascular risk factors were considered.
Results With univariate analysis, higher values of homo-
cysteine and Lp(a) (OR 4.24, 95% CI 2.01–8.94, p<
0.0001; OR 1.32, 95% CI 1.04–1.67, p=0.03, respectively)
and lower values of vitamin B6 (OR 0.44, 95% CI 0.25–
0.76, p=0.003) were significantly associated with NAION.
At multivariate analysis, adjusted for age, gender, smoking
habit, hypertension, dyslipidemia, diabetes, sleep apnea,
and thrombophilic risk factors, the higher homocysteine
and Lp(a) values (OR 5.74, 95% CI 2.41–13.67, p =
0.0001; OR 1.27, 95% CI 1.01–1.63, p=0.04) and lower
vitamin B6 values (OR 0.42, 95% CI 0.23–0.77, p=0.005)
maintained their significant relationship with NAION.
Conclusions This study demonstrated that elevated plasma
homocysteine and lipoprotein(a) levels, as well as low
vitamin B6 levels, may increase the risk of developing
NAION. A screening for these thrombophilic markers
could be useful in subjects experiencing NAION.
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Introduction
Non-arteritic anterior ischemic optic neuropathy (NAION)
is a relatively frequent cause of severe visual impairment in
subjects older than 50 years [7, 31]. It is a multifactorial
disease that occurs because of an acute perfusion insuffi-
ciency in short posterior ciliary arteries (SPCAs) leading to
optic nerve head (ONH) ischemia.
A variety of risk factors for NAION have been identified.
The disease was associated with genetic factors, as a small
and crowded disc, and traditional cardiovascular risk factors,
as arterial hypertension, diabetes mellitus, dyslipidemia,
sleep apnea, and coronary artery disease [3, 10, 11, 14, 18,
21, 22, 28, 32]. Since the late 1990s, several observations
have suggested that hypercoagulable states may also be
pathogenetically relevant [5, 15, 25, 26, 29, 35, 37]. Among
thrombophilic markers, elevated homocysteinemia and lipo-
protein(a) [Lp(a)] plasma levels seem to be particularly
significant [15, 26, 29, 30, 37, 39]. They have to be
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considered as predisposing factors. However, the develop-
ment of NAION is strongly related to acute ONH hypo-
perfusion, which is mostly due to nocturnal hypotension [14,
19–21, 23].
Aim of the present case-control study was to investigate
the role of traditional and emerging risk factors, that is
homocysteine and lipoprotein(a), on the occurrence of
NAION.
Materials and methods
A total of 85 consecutive patients with a first episode of acute
unilateral NAION who had referred to the Eye Clinic of the
University of Florence were included in the study. Diagnosis
of NAION was based on clinical findings (decrease in visual
acuity, dyschromatopsia, absence of ocular pain, relative
afferent pupillary defect, sectorial or diffuse ischemic papil-
lary oedema, peripapillary hemorrhages, visual field defects
consistent with the ophthalmoscopic features). Erythrocyte
sedimentation rate and C-reactive protein serum levels were
determined to exclude arteritic anterior ischemic optic
neuropathy. One hundred and seventy age- and gender-
matched healthy subjects were recruited from relatives or
friends of patients and considered as controls. All participants
gave signed informed consent; the study was approved by the
local Ethics Committee and applies with the Declaration of
Helsinki. Patients and controls with a personal history of
abnormal liver or renal function, thyroid disease, and any
other ocular pathologies other than NAION were excluded.
Patients and controls underwent a detailed interview
addressed to the presence of cardiovascular diseases and risk
factors, including arterial hypertension, diabetes mellitus,
dyslipidemia, smoking habit, and sleep apnea, and a complete
physical and ophthalmic examination. The subjects were
classified as having hypertension and diabetes according to
the guidelines of European Society of Hypertension/European
Society of Cardiology and to those of the American Diabetes
Association, respectively [8, 13]. Dyslipidemia was defined
following the criteria of the ATP III Expert Panel of the US
National Cholesterol Education Program [27].
Blood samples were collected into evacuated plastic
tubes (Vacutainer) from the basilic vein, after an overnight
fasting. Cholesterol and trigliceride values were determined
by means of enzymatic and colorimetric methods, respec-
tively. To determine homocysteine (Hcy) and C677T
methylenetetrahydrofolate reductase (MTHFR) polymor-
phism, whole venous blood was collected in tubes contain-
ing ethylenediaminetetraacetate (EDTA) 0.17 mol/L,
immediately put in ice, and centrifuged within 30 min at
4°C (1,500 x g for 15 min). Plasma samples were stored at
−20 °C until assay. Plasma levels of total Hcy (free and
protein bound) were measured by fluorescence polarization
immunoassay (IMX Abbott Laboratories, Oslo, Norway).
C677T MTHFR polymorphism analysis was performed
through electronic microchip technology (Nanogen, San
Diego, CA, USA). To determine circulating vitamins (B6,
B12, and folic acid) venous blood was put in tubes without
anticoagulant and centrifuged at room temperature (2,000 x g
for 15 min). Sera samples were stored at −20 °C until assay.
Vitamin B6 levels were determined by using a commercial
HPCL assay with fluorescence detection (Immundiagnostik
AG, Bensheim, Germany), whereas sera levels of folic acid
and vitamin B12 were measured by radioimmunoassay (ICN
Pharmaceuticals, Orangeburg, USA). Sera for testing lipo-
protein(a) were obtained by centrifuging blood collected in
evacuated tubes without anticoagulant and stored at −20 °C
until assay. Lp(a) levels were determined by an ELISA assay
(Apo[a] ELISA, Mercodia, Uppsala, Sweden).
Results are shown as median and range or number (n)
and rate (%). Statistical comparisons between groups were
carried out by means of Student’s t-test and Chi-square test.
A logistic regression analysis was used to evaluate the risk
of NAION according to the presence of any risk factor. All
the considered variables, that means demographic data and
atherosclerotic and thrombophilic risk factors, were intro-
duced in the multivariate model. Odds ratio (OR) and 95%
confidence intervals (CI) were presented. Statistical signif-
icance was set at p<0.05.
All statistical analyses were performed using the SPSS
(Statistical Package for Social Sciences, Chicago, USA)
software for Windows (Version 13.0).
Results
Demographic and clinical characteristics of the participants
to the study are outlined in Table 1.
Arterial hypertension and dyslipidemia were significant-
ly more prevalent in patients than in controls, whereas the
prevalence of other traditional risk factors for atheroscle-
rotic diseases, as smoking habit and diabetes, was not
Table 1 Demographic and clinical characteristics of NAION (non-
arteritic anterior ischemic optic neuropathy) patients and controls
(Student’s t-test, Chi-square test)
NAION Controls p-value
Age (years) * 65 (26–88) 65 (21–84) 0.4
Males, n (%) 39 (45.9) 75 (44.1) 0.9
Hypertension, n (%) 51 (60) 40 (23.5) <0.0001
Smoking habit, n (%) 17 (20) 24 (14.1) 0.2
Dyslipidemia, n (%) 41 (48.2) 55 (32.4) 0.01
Diabetes, n (%) 4 (4.7) 5 (2.9) 0.5
*Median (range)
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significantly different between the two groups. None of the
examined subjects reported a history of sleep apnea.
Among thrombophilic risk factors, plasma levels of Hcy
and Lp(a) resulted significantly higher in patients with
NAION compared with controls. Significant differences for
vitamin B6, but not for vitamin B12 and folic acid, were
observed between patients and healthy subjects. MTHFR
C677T polymorphism resulted not to be significantly
different between the two groups (Table 2).
In order to investigate the possible relationship between
the presence of thrombophilic risk factors and development
of NAION, we logarithmically (natural logarithm [Ln])
transformed Hcy, vitamin B6, and Lp(a) plasma values, and
we performed a logistic regression analysis with these
parameters evaluated as continuous variables.
With univariate analysis, higher values of Hcy and Lp(a)
were found to be significantly associated with the occur-
rence of NAION (p<0.0001 and p=0.03, respectively).
Conversely, lower values of vitamin B6 resulted to be
protective against this disease (p=0.003).
With multivariate analysis, adjusted for all the consid-
ered variables, the odds ratio for lower values of vitamin B6
and for higher levels of Lp(a) resulted slightly lower, but
remained statistically significant (p=0.005, p=0.04, respec-
tively). To what extent Hcy, its plasmatic increase was even
more significantly associated with NAION, determining an
almost six-fold increase in the odds of having the disease
(p<0.0001) (Table 3).
Discussion
Non-arteritic anterior ischemic optic neuropathy has a
multifactorial aetiopathogenesis. Recent reviews have sum-
marized the conditions more frequently associated with an
increased risk of developing the disease: a crowded optic
disc, atherosclerosis, diabetes, dyslipidemia, hypertension,
hypercoagulable states, smoking habit, sleep apnea, ischemic
heart disease, and cerebrovascular diseases [23, 30].
All the mentioned conditions act as predisposing factors,
which renders ONH more susceptible to ischemia. In fact,
they may have a negative effect on the ONH circulation by
producing an endothelial damage at SPCAs level. Never-
theless, the underlying mechanism for the development of
NAION is not an atherothrombotic event, but an acute,
severe blood-flow reduction in prelaminar and laminar
areas of lamina cribrosa that are supplied by SPCAs.
Nocturnal hypotension has been identified as the precipi-
tating factor in individuals affected with traditional and
emerging cardiovascular risk factors [14, 19–21, 23].
In this study we performed a joint analysis of traditional
cardiovascular and thrombophilic risk factors in patients
presenting with unilateral acute NAION. We found that
arterial hypertension and dyslipidemia (but not diabetes and
smoking habit) were significantly more prevalent in
patients than in controls. The vast majority of the studies
published by now have reported a higher prevalence of
hypertension, hypercholesterolemia, and diabetes in
patients with NAION, but some authors did not confirm
these data [10, 22, 23, 26, 29–32, 38]. The lacking
association between diabetes and NAION in our trial is
certainly strange. A possible reason for this finding could
be the inclusion of young patients, but we really are not
able to give a credible justification.
With respect to thrombophilia, our results clearly
demonstrated that in patients with NAION, compared to
healthy subjects, plasma levels of Hcy and Lp(a) are
increased, whereas those of vitamin B6 are reduced.
Hyperhomocysteinemia has a well-established prothrom-
botic effect by producing severe endothelial damage [17,
36]. This can be due to polymorphisms in genes encoding
for enzymes involved in Hcy metabolism (as homozygosity
to the C677T MTHFR polymorphism) or to a decrease in
the uptake of vitamins B6, B12, and folic acid, cofactors of
Hcy metabolism. In particular, an impaired vitamin B6
status is related to an increased risk of thrombotic events
because it may induce hyperhomocysteinemia and affect
Table 2 Plasma values of homocysteine, vitamins, lipoprotein(a), and
assessment of methylenetetrahydrofolate reductase (MTHFR) poly-
morphism in NAION (non-arteritic anterior ischemic optic neuropa-
thy) and controls population (Student’s t-test)
NAION Controls p value
Homocysteine,
μmol/L
12.3 (6.2–34.1) 10.8 (2.4–27.8) 0.003
Folic acid, ng/mL 3.3 (0.3–20.7) 3.4 (1.0–20.0) 0.9
Vitamin B6, ng/mL 5.6 (1.5–20.6) 7.3 (1.6–21.2) 0.003
Vitamin B12, pg/mL 343.5 (53–816) 389.0 (20–991) 0.1
Lipoprotein(a), mg/L 120.0 (1–1196) 72.5 (1–580) 0.01
MTHFR C677T
CC, n (%) 18 (21.2) 41 (24.1)
TC, n (%) 46 (54.1) 94 (55.3)
TT, n (%) 21 (24.7) 35 (20.6) 0.1
T allele 0.52 0.48 0.2





Ln homocysteine, μmol/L 4.24 (2.01–8.94) 5.74 (2.41–13.67)
Ln Lp(a), mg/L 1.32 (1.04–1.67) 1.27 (1.01–1.63)
Ln vitamin B6, ng/mL 0.44 (0.25–0.76) 0.42 (0.23–0.77)
* Adjusted for demographic data and atherosclerotic and thrombo-
philic risk factors
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platelet aggregation [16, 33, 34]. To date, no literature
exists about the role of vitamin B6 circulating values in
NAION. Currently, there is controversy regarding the
hypothesis that thrombophilia may be involved in the
development of NAION. In fact, several authors have
observed a higher prevalence of factor V Leiden, elevated
Lp(a) serum levels, and hyperhomocysteinemia in subjects
with NAION [15, 25, 26, 29, 35–37, 39]. However, these
findings were not confirmed in larger populations [5, 32].
Of note, the study conducted by Salomon et al. did not
demonstrate an association between the disease and any
inherited and acquired thrombophilic factor [32].
Lipoprotein(a) is a defined marker of hypofibrinolysis,
which may determine thrombophilic states leading to
cardiovascular and cerebrovascular diseases [12]. Our
results are in keeping with those of Nagy et al., who stated
that elevated Lp(a) was a main predictor for NAION [26].
In summary, the present study strengthens the concept
that cardiovascular risk factors, both traditional and
thrombophilic, are predisposing risk factors for NAION.
Our study has, however, some limitations. Only fasting
homocysteinemia has been considered; measurements of
Hcy post-methionine plasma levels could be useful to
reveal an impairment of Hcy metabolism in a number of
subjects. In addition, nutritional habits have not been
registered; they would be important to determine the role
of diet on vitamin B6 and homocysteine circulating values.
The complex, multifactorial nature of NAION has
remarkable implications on the management of affected
individuals. A complete assessment of traditional cardio-
vascular risk factors and a screening for thrombophilia
could be performed. Although there are no guidelines for
therapeutical management of NAION, some interventions
deserve to be recommended. Arterial hypertension, noctur-
nal hypertension, dyslipidemia, and sleep apnea must be
treated. Discontinuation of tobacco smoking would be
advisable. To what extent prothrombotic and hypofibrino-
lytic states, some of them do not have specific treatments,
while others do. Of note, plasma levels of homocysteine
can be easily and effectively lowered by daily vitamin
supplementation (vitamins B6, B12, and folic acid). This
treatment demonstrated to produce a considerable reduction
of cardiovascular morbidity in subjects with arterial
occlusive disorders [9]. Kupersmith et al. showed that
aspirin treatment would prevent the involvement of the
fellow eye in the 2 years after the first episode of NAION
[24]. Conversely, larger studies have denied a long-term
prophylactic effect [4, 6]. Thus, at present antiplatelet
treatment cannot be proposed as a treatment of choice for
NAION patients. However, even if referred only to our
study, aspirin treatment could possibly be suitable to reduce
Lp(a) plasma levels, as demonstrated by Akaike and
coworkers [1].
In conclusion, the present study indicates that a complete
assessment of traditional and thrombophilic risk factors
could be advisable in patients with NAION. Our findings
may suggest the potential utility of different and combined
therapeutical approaches which aim at lowering the
incidence of further cardiovascular disorders and of the
involvement of the second eye: the treatment of arterial
hypertension and dyslipidemia, the correction of hyper-
homocysteinemia by vitamin supplementation, and, if the
study by Akaike et al. is confirmed, the reduction of Lp(a)
plasma levels by aspirin [1]. Longitudinal and intervention
studies are needed to establish the influence of the aforesaid
risk factors and their therapeutical management on the
cardiovascular morbidity and the visual prognosis in
subjects presenting with NAION.
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